Outcomes and Therapeutic Management of Bladder Cancer

• Autore: Moschini Marco
• Pubblicazione: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020
• Descrizione fisica: 1 online resource (120 p.)
• Soggetto topico: Medicine
• Soggetto non controllato: adjuvant; age; anesthesia recovery periods; biomarkers; bladder cancer; chemotherapy; clear-cell adenocarcinoma; cognitive impairment; female; FOXA1; gamma-cyclodextrins; GATA3; glycogen; human epidermal growth factor receptor 2; immunotherapy; indoleamine 2,3-dioxygenase; intracorporeal neobladder; KRT20; methylation; molecular markers; mRNA; muscle-invasive bladder cancer; n/a; neoadjuvant; neuromuscular blockade; nodal disease; open; outcome; outcomes; PCR; pN1; programmed death ligand-1; propensity score; radical cystectomy; robotic; robotic radical cystectomy; robotic-assisted; SEER program database; sex-sparing; survival; urinary bladder; urothelial carcinoma
• Persona (resp. second.): MoschiniMarco
• Sommario/riassunto: Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.
• Titolo autorizzato: Outcomes and Therapeutic Management of Bladder Cancer
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910557114503321
• Lo trovi qui: Univ. Federico II